<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="28951"><DrugName>atecegatran fexenetil</DrugName><DrugNamesKey><Name id="42929688">atecegatran</Name><Name id="42956093">atecegatran metoxil</Name></DrugNamesKey><DrugSynonyms><Name><Value>thrombin inhibitors, AstraZeneca</Value></Name><Name><Value>AZD-0837</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AR-H069927XX</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>AR-H067637XX</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>atecegatran</Value><Types><Type>INN</Type></Types></Name><Name><Value>atecegatran fexenetil</Value></Name><Name><Value>AR-H067637</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>atecegatran metoxil</Value><Types><Type>INN</Type></Types></Name><Name><Value>372523-38-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>516491-10-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>433937-93-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>609847-38-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14190">AstraZeneca plc</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28951" type="Drug"><TargetEntity id="328026" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"></TargetEntity><TargetEntity id="D013927" type="MeSH"></TargetEntity><TargetEntity id="304" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"></TargetEntity><TargetEntity id="D001281" type="MeSH"></TargetEntity><TargetEntity id="-1073626038" type="omicsDisease"></TargetEntity><TargetEntity id="194" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity><SourceEntity id="PTGT-00713" type="ciTarget"><TargetEntity id="161932276721473" type="siTarget">Prothrombin</TargetEntity><TargetEntity id="1159" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1076">Thrombosis</Indication><Indication id="1542">Atrial fibrillation</Indication></IndicationsSecondary><ActionsPrimary><Action id="111">Factor IIa antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="659">Coagulation inhibitor</Action><Action id="449">Antiarrhythmic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="667">Peptidomimetic</Technology><Technology id="660">Oral sustained release formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>B1E</Code><Name>DIRECT THROMBIN INHIBITORS</Name></Ephmra><Ephmra><Code>C1B</Code><Name>ANTI-ARRHYTHMICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-30T11:49:02.000Z</LastModificationDate><ChangeDateLast>2017-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>2000-06-02T11:59:33.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Atecegatran metoxil (AZD-0837; structure shown), the lead in a series of oral peptidomimetic thrombin inhibitors and a follow-up to &lt;ulink linkID="13533" linkType="Drug"&gt;melagatran&lt;/ulink&gt;, was under development by &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; (AZ) for the potential treatment of thrombosis and atrial fibrillation (AF) [&lt;ulink linkID="368646" linkType="reference"&gt;368646&lt;/ulink&gt;], [&lt;ulink linkID="815213" linkType="Reference"&gt;815213&lt;/ulink&gt;]. Initial phase II trials confirmed the drug's pharmacology, but a short half-life precluded once daily dosing, so the company formulated the drug as an extended-release product. In July 2008, the company confirmed that it had decided to progress the formulation into phase III development for the prevention of stroke in patients with AF [&lt;ulink linkID="930119" linkType="Reference"&gt;930119&lt;/ulink&gt;], [&lt;ulink linkID="930079" linkType="Reference"&gt;930079&lt;/ulink&gt;], and in July 2008, the product was listed in  phase III development for thrombosis [&lt;ulink linkID="930119" linkType="Reference"&gt;930119&lt;/ulink&gt;], [&lt;ulink linkID="930079" linkType="Reference"&gt;930079&lt;/ulink&gt;]. However, in October 2008, the company announced that due to formulation stability issues it would not be able to continue with phase III trials until 2009  [&lt;ulink linkID="957705" linkType="Reference"&gt;957705&lt;/ulink&gt;].  In July 2009, the product was still listed in AstraZeneca's pipeline as  in phase II development for thrombosis [&lt;ulink linkID="1030032" linkType="Reference"&gt;1030032&lt;/ulink&gt;]. The program was finally discontinued in July 2010 [&lt;ulink linkID="1119693" linkType="Reference"&gt;1119693&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Several patents filed by AstraZeneca  (eg &lt;ulink linkID="PA158273" linkType="Patent"&gt;WO-0244145&lt;/ulink&gt;, &lt;ulink linkID="PA2881575" linkType="Patent"&gt;WO-03101424&lt;/ulink&gt;, &lt;ulink linkID="PA2881574" linkType="Patent"&gt;WO-03101423&lt;/ulink&gt; and &lt;ulink linkID="PA2881699" linkType="Patent"&gt;WO-03101957&lt;/ulink&gt;) specifically relate atecegatran metoxil.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2008, filing in the US and Europe was expected in 2012 [&lt;ulink linkID="872532" linkType="Reference"&gt;872532&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Extended-release formulation&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2009, the Korean FDA approved a multicenter, randomized, double-blind, parallel-group phase III trial to compare atecegatran metoxil with warfarin in patients with atrial fibrillation [&lt;ulink linkID="995138" linkType="Reference"&gt;995138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, phase III trials were in preparation but it was announced that, due to stability problems with the atecegatran metoxil tablets to be used, the trials would be delayed from the fourth quarter 2008 until 2009 [&lt;ulink linkID="957705" linkType="Reference"&gt;957705&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2008, exposure data were presented. At that time the longest exposure had been 16 months. In various studies (-8, -42 and -51) a number of AF patients had been treated for several months. The incidence of liver ALT increases was low and comparable to warfarin. The relationship of dose/plasma levels was predictable and PK variability was minimal at a dose selected using biomarkers, modelling and experience with &lt;ulink linkID="13533" linkType="Drug"&gt;melagatran&lt;/ulink&gt;. The ER formulation gave advantages of once-daily treatment with a smoothing of peaks and troughs. There were no food interactions and low drug-drug interactions. Data from phase IIb studies were expected to be presented later in 2008 [&lt;ulink linkID="930472" linkType="Reference"&gt;930472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2007, a randomized, open-label, active control, parallel assignment phase II trial (NCT00623779; D1250C00051) was initiated in  subjects (expected n =   150) with nonvalvular AF, who were unable or unwilling to take vitamin K antagonists (VKAs), in  Europe and Russia. The  subjects were to receive the ER formulation of atecegatran metoxil with aspirin for up to 3 months.   The primary endpoint was to assess the feasibility of conducting a  trial in this study population by evaluation of drop-out rate and compliance with treatment and study procedures. The study was expected to be complete in May 2008 [&lt;ulink linkID="881117" linkType="Reference"&gt;881117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2007, clinical data on atecegatran metoxil were presented at the 21st International Society on Thrombosis and Hemostasis Congress in Geneva, Switzerland. AF patients (n = 250) with at least one additional risk factor were randomized for treatment with 150- or 350-mg atecegatran metoxil bid with warfarin (INR2-3, open treatment) for 3 months. No cases of ischemic stroke, transient ischemic attack or cerebral hemorrhage occurred in any of the patients. The safety and tolerability of 150-mg atecegatran metoxil bid was similar to warfarin. Bleeding events were less frequent with atecegatran metoxil 150 mg bid than warfarin and more frequent with 350-mg atecegatran metoxil bid. Increased alanine aminotransferase (&amp;gt; 3-fold) was rare with no difference in the groups. Serious adverse events were more common in the 350-mg atecegatran metoxil group [&lt;ulink linkID="815213" linkType="Reference"&gt;815213&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2006, phase II results had shown that the drug could be differentiated from melagatran in terms of liver signal, but the drug was shown to have a short half-life.  By that time, AstraZeneca had decided to develop an ER formulation. Although early development had suggested that the approach was feasible, it would probably take up to 2 years to generate enough data for the new formulation to enter phase III trials [&lt;ulink linkID="648480" linkType="Reference"&gt;648480&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  February 2006, phase I trials were ongoing  in Japan   [&lt;ulink linkID="594874" linkType="Reference"&gt;594874&lt;/ulink&gt;], [&lt;ulink linkID="648528" linkType="Reference"&gt;648528&lt;/ulink&gt;].     &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Original formulation&lt;/subtitle&gt;By September 2005, a phase II trial had begun in 100 patients who were receiving atecegatran metoxil for over 3 months [&lt;ulink linkID="624516" linkType="Reference"&gt;624516&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II trials in thrombosis had been initiated by October 2004 [&lt;ulink linkID="563075" linkType="Reference"&gt;563075&lt;/ulink&gt;], [&lt;ulink linkID="563036" linkType="Reference"&gt;563036&lt;/ulink&gt;]; these were ongoing in July 2005 [&lt;ulink linkID="615253" linkType="Reference"&gt;615253&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By October 2002, new mimetics of the tripeptide D-Phe-Pro-Arg had been synthesized using either cyclopentenedicarboxylic derivatives or a cyclohexenedicarboxylic derivative as surrogate for proline. Arginine was substituted with 4-amino-methylbenzamidine and tertiary amides were optimized as Phe replacement. The lead candidate exhibited an IC50 value of 49 nM [&lt;ulink linkID="493458" linkType="reference"&gt;493458&lt;/ulink&gt;]. By February 2003, further mimetics had been synthesized using a 4-amino-2-carboxymethyl-3-morpholinone structural motif as surrogate for D-Phe-Pro. The best inhibitor exhibited an IC50 value of 0.130 microM and the X-ray crystal structure of the inhibitor cocrystallized with alpha-thrombin was resolved [&lt;ulink linkID="525640" linkType="reference"&gt;525640&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data published in 2002 disclosed a series of indolizidinone derivatives. The lowest IC50 values were achieved with a 3-benzyl analog but results suggested that optimization of the size and complementary polarity of the S2 pocket and the C-7 substituent as directions to increase inhibitory activity [&lt;ulink linkID="467080" linkType="reference"&gt;467080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, a library of thrombin inhibitors were synthesized and evaluated using various combinatorial techniques. Several compounds from the series showed reasonable thrombin inhibition with pIC50 values in the range 4.25 to 7.60, which correlated well with theoretical values in most cases [&lt;ulink linkID="424763" linkType="reference"&gt;424763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2000, a series of non-peptidic thrombin inhibitors had been prepared by replacing the amino acids of the thrombin-inhibiting tripeptide chain of D-Phe-Pro-Arg with isosteres. The most potent compound had an IC50 value of 0.98 microM [&lt;ulink linkID="368646" linkType="reference"&gt;368646&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-29T00:00:00.000Z</StatusDate><Source id="1119693" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-29T00:00:00.000Z</StatusDate><Source id="1119693" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-06-02T11:59:33.000Z</StatusDate><Source id="368646" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-02T00:00:00.000Z</StatusDate><Source id="507400" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-07-06T00:00:00.000Z</StatusDate><Source id="815213" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="881117" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-01T00:00:00.000Z</StatusDate><Source id="594874" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="930079" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="930119" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-10-06T00:00:00.000Z</StatusDate><Source id="563075" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="881117" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00713"><Name>Factor IIa</Name><SwissprotNumbers><Swissprot>P00734</Swissprot><Swissprot>P00735</Swissprot><Swissprot>P18292</Swissprot><Swissprot>P19221</Swissprot><Swissprot>P84122</Swissprot><Swissprot>Q5R537</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COc1ccc(c(c1)N(C2CCCCC2)C(=O)C3=CCCC3C(=O)NCc4ccc(cc4)C(=N)N)OC</Smiles><Smiles>c1cc(ccc1CNC(=O)[C@@H]2CCN2C(=O)[C@@H](c3cc(cc(c3)Cl)OC(F)F)O)C(=N)N</Smiles><Smiles>CCc1cc(cc(c1)OS(=O)(=O)c2ccccc2)OCCc3ccc(cc3)C(=N)N</Smiles><Smiles>COc1ccc(c(c1)S(=O)(=O)NN2CCO[C@H](C2=O)CC(=O)NCc3ccc(cc3)C(=N)N)OC</Smiles><Smiles>CO/N=C(/c1ccc(cc1)CNC(=O)[C@@H]2CCN2C(=O)[C@@H](c3cc(cc(c3)Cl)OC(F)F)O)\N</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1009341" number="WO-00244145" title="New mandelic acid derivatives and their use as thrombin inhibitors"></PatentFamily><PatentFamily id="1515844" number="WO-2008068475" title="New crystalline forms"></PatentFamily><PatentFamily id="1682069" number="WO-2005054168" title="New process"></PatentFamily><PatentFamily id="1806619" number="WO-03101423" title="Immediate release pharmaceutical formulation"></PatentFamily><PatentFamily id="2137749" number="WO-03101956" title="Pharmaceutical combination"></PatentFamily><PatentFamily id="2324696" number="WO-03101957" title="New salts"></PatentFamily><PatentFamily id="400609" number="WO-03101424" title="Modified release pharmaceutical formulation"></PatentFamily><PatentFamily id="421687" number="WO-03000293" title="Pharmaceutical formulation"></PatentFamily><PatentFamily id="554036" number="WO-2009027745" title="Pharmaceutical formulation for extended release"></PatentFamily><PatentFamily id="957027" number="WO-2006090153" title="Process for preparing protected amidines"></PatentFamily><PatentFamily id="995348" number="WO-2006125964" title="A process for the dynamic resolution of (substituted) (R)- or (S)-mandelic acid"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CARBOGEN AMCIS AG" id="1033379"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>